Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
triple-negative breast cancer
Biotech
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma landed a global license for $7 million upfront, plus up to $287.3 million in milestones, and plans to target breast and small cell lung cancer.
Nick Paul Taylor
Sep 21, 2022 9:05am
CytomX puts lead ADC on the block after phase 2 data underwhelm
Jul 7, 2022 8:45am
An mRNA therapy might boost response to I-O in breast cancer
Mar 22, 2022 9:10am
Heart arrhythmia drug reduces tumor spread in cancer mouse model
Jan 18, 2022 8:55am
Sanofi inks $270M cancer AI deal with developer Owkin
Nov 18, 2021 1:30am
Targeting tumor-driving RNA proteins in aggressive breast cancer
Jul 2, 2021 11:00am